Company Profile
Isomorphic Labs (Google DeepMind)
— An Alphabet AI drug-discovery company spun out of the research organization that created AlphaFold
Isomorphic Labs is an Alphabet drug-discovery company created from DeepMind (now Google DeepMind) in 2021. Its founder and CEO, Demis Hassabis, co-founded and leads Google DeepMind and shared the 2024 Nobel Prize in Chemistry for work on AlphaFold, the AI system for predicting protein structures. Isomorphic Labs jointly developed AlphaFold 3 with Google DeepMind and announced it in May 2024. The privately held company does not disclose revenue, but it raised $2.1 billion in a Series B round in May 2026 and has research collaborations with Eli Lilly, Novartis, and Johnson & Johnson. This article explains what the company is investing in, whom it works with, and what it aims to achieve in AI-enabled drug discovery, using official company releases, Alphabet’s annual report, and peer-reviewed research.
- Isomorphic Labs in 30 seconds and its position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company scale (privately held; assessed through funding and headcount)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What Isomorphic Labs aims to achieve in drug discovery and DDS
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary, sources, and claim-to-source table
1. Isomorphic Labs in 30 seconds and its position in drug discovery and DDS
IsoDDEAlphaFold 3 was co-developed with Google DeepMind
Businesses related to drug discovery and DDS are largePharmaceutical Company / Biotech / Contract Development Manufacturing (CDMO・CRO)3 types. Isomorphic LabsDrug discovery biotechA company specializing in medicine with AI FactsHome conf ,Google DeepMind and Isomorphic LabsComment Google DeepMind is an AI research organization of Alphabet. Isomorphic Labs is divided into 2021.PharmaceuticalComment In 2024, the company explained, “Autonomously operated in Alphabet, has dedicated resources and focus on the application of AI drug discovery.” To connect both peopleThe CEO is the same Mr. HasabisHomeAlphaFold 3Comment Google DeepMind is not an explanation of Google DeepMind itself.
2. Logo and company name
Name: Isomorphic Labs(IsoLabs and Iso) The company name isomorphic comes from the idea that there may be a common structure between biology and information science, according to the announcement of Mr. Hasabis. "Organization Mind" was established in 2021.Google DeepMindIt is written as ".
Official Site:https://www.isomorphiclabs.com/3. Where is this company in the world of drug discovery and DDS?
TypeDrug discovery biotechHome FactsHome Lilly Nov s, 2024LowHowever, In partnership with Johnson & Johnson in January 2026, we explain how to use design capability across low-ability, antibody, peptide, and paste. Target modalitiesSpreading from low to large)s (biopharmaceu)s)Stage Our candidatesCancer and ImmunityThe company is responsible for the area of The basics of AI drug discovery are handled by the technical commentary "AI drug discovery and screening".
Google DeepMind
| Types of Source | ||
|---|---|---|
| Born | Autonomous Subsidiary Launched from Alphabet's Mind in 2021 | Company release |
| Company | Mr. Hasabis, Founder and CEO of Google DeepMind | Company release |
| AlphaFold 3 | Isomorphic Labs and Google DeepMind jointly developed and announced in Nature in May 2024. The core contributors of the paper line up the affiliation of both organizations | Company articles and review papers |
| Nobel Prize | Half of the Nobel Chemical Award in 2024 was awarded by Google DeepMind’s Hasabis and Jumper with “protein structure prediction” | Nobel Foundation |
| Positioning parent company | Alphabet’s 10-K is one of Other、s. “We are rethinking from the first principle of drug discovery to accelerate the development of new drugs using AI.”No individual disclosure of business results | Alphabet Form 10-K |
Company size (unlisted), uncertain, see number of people
Isomorphic LabsNon-listedNo sales, profit and loss, and R&D expenses Undetermined / FutureHome The parent company Alphabet 10-K does not disclose Isomorphic Labs numbers from "Other Labs". Instead the company has publishedFundraising/Partnership Prepaid/PersonnelIndicates the scale.
| Time | Home | Price | Home |
|---|---|---|---|
| January 2024 | Prepayment for joint research with Lilly | $45 million | Eli Lilly |
| January 2024 | Prepayment for joint research with Nov)s (some research expenses will be borne by Nov)s) | 3,750 million yen | Novartis |
| March 2025 | First external funding | $6 billion | Thrive Capital, GV, Alphabet |
| May 2026 | Series B | $2.1 billion | Led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Unit |
| Total | Simple total of the above-mentioned amount | US$28.00 | with different personality funds The calculation of this paper |
In November 2025, the staff members visited “London Lausanne Cambridge (USA)”Over 300"It is FactsHome The release of Series B is important to use the procurement funds for AI, engineering, drug discovery, and clinical human resources, but the number of recruitment goals is not written. Funds before $6 billion in March 2025 (investment from Alphabet) are not published Undetermined / Future。
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| Person | Over 300 people (November 2025). Engineers, Scientists and Operations Mr. Max Jedderberg, President and CEO, formerly Chief AI Officer, was appointed as January 2026. | Facts |
| Location | London Cross head office, Lausanne (May 2023) Opened in EPFL Innovation Park, Cambridge, USA (June 2025). Kendall Square | Facts |
| Human (Clinical System) | In June 2025, Dr. Ben Wolf, who has experience in precise medical care in the cancer field, was appointed as the Chief Medical Officer and medical personnel in the US base | Facts |
| Gold (R&D expenses) | Non-discrete | Non-public |
| ulation resources and data | Explanation that there is a study environment that rotates large amounts of experiments on computers and a set of independently developed life science data (the company called dataverse). Non-dis sure | Facts |
| External investment, acquisition and introduction | No publication on investments, acquisitions or compounds in other companies | Not confirmed |
| Experiment (Wet Lab) | In partnership with J&J, Isomorphic Labs will explain the projection and design on the computer, and J&J will evaluate the experiment. Non-dis sure of the scale of our laboratory facilities | Facts |
| Graduate School | Lausanne is located in the Innovation Park of EPFL (Lausanne). There is no publication of joint research with funds. AlphaFold 3 codes and weights are published for academic use in November 2024 | Facts |
Isomorphic LabsR&D expenses, sales, company pipeline item name, target nameHome Undetermined / FutureHome In-house programs are described as "mainly cancer and immunity", and the code name of the candidate compound is not disclosed. The company of AI drug discovery tends to report large amounts of prepayment and procurement of affiliation.I can’t see how many programs are distributedAt this point is the limit.
6. Past Initiatives
| Time | Home | |
|---|---|---|
| Year 2020 | DeepMind’s AlphaFold 2 predicts the three-dimensional structure of protein from the amino acid sequence with 、ic level accuracy (in the company’s announcement) | |
| November 2021 | Isomorphic Labs(Hasabi) | AlphaFold |
| May 2023 | Established the second base in Lausanne, Switzerland | European Researchers |
| January 2024 | Lilly(prepaid $45 million, milestone up to $17 billion)NovartisJoint research with two companies (prepaid $37.5 million, milestone up to $12 billion). Low s | Partnership with the first pharmaceutical company |
| May 2024 | AlphaFold 3Google DeepMind Predicting the structure of complexes such as protein, DNA, RNA, and low s | Directly handles drug and target bonds, the core problem of drug discovery |
| October 2024 | Hasabis and Nobel Chemical Award (protein structure prediction) | Evaluation of technology |
| November 2024 | AlphaFold 3 codes and weights for academic use | Sharing the technology and technology left in the company |
| February 2025 | Expanded partnership with Nov)s (up to three programs in the same conditions) | 1 year |
| March 2025 | First external funding $6 billionHome A statement that our program is used for clinical development | From "Affiliation Center" to "A company with own products" |
| June 2025 | Appointment of Chief Medical Officer and Opening of Cambridge Office | Building a System for Clinical Development |
| January 2026 | Johnson & JohnsonJoint research on multiple modalities and multiple targets (Janssen Biotech) | Expanded target for large s such as antibodies |
| February 2026 | Design SystemIsoDDEAnnouncement of Technical Report | AlphaFold 3 |
| May 2026 | $2.1 billion Series B | Expanded the scale of funding |
Isomorphic LabsClinical trials are not publishedClinicalTrials.gov does not see the trial of the company Undetermined / FutureHome Therefore, there are no results of approval or clinical trials that can be introduced in this article.
7. Future plans
Pipeline AdvanceRelease of Series B in May 2026
The following are not listed in the company's publication materials Undetermined / Future。
First timeStart of clinical trials・Participation with J&JPricePartnership with Lilly NovosTarget and Prog／R&D expenses and sales/Evaluation (Corporate Value) "Isomorphic Labs' evaluation amount is USD 250 million" and "In the year of clinical trials"
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| From a research company earning in partnershipA company that clinically produces drugsI want to move to | In March 2025, he said, “I am applying my own program to clinical development,” and appointed the Chief Medical Officer in June of the same year to establish a U.S. base. | Facts |
| First clinical productCancerlikely to be | Cancer and immunity The Chief Medical Officer is a specialist in precision medicine for cancer and has been involved in the development of low-velo kinase inhibitors in the previous position | |
| Contact UsBiopharmaceuticalClose | In 2024, only low。s and 2026 J&J alliances include antibodies, peptides and mole。 glues. IsoDDE Technical Report Handles Antibody and Antigen Interface Prediction | |
| Technology (AF3) and IsoDDESeparate and maintain competitiveness | While AF3 has published code for academic purposes, IsoDDE does not disclose the model itself by simply showing the end of performance in technical reports | |
| The source of competitivenessulation resources and dataContact Us | J&J tie-up release highlights the unique data and large-scale GPUs on ‘Planet Scale Computing Capabilities’ and technical introduction pages |
AlphaFold 3 was published as a paper in May 2024.Code and weight for academic useHome FactsHome On the other hand, IsoDDE announced in February 2026, the company claims that the accuracy of AlphaFold 3 was doubled or higher in the technical report, and the prediction of low- binding affinity exceeded the standard method based on physical calculations. The model itself is not published FactsHome This article is here"The foundation of research is published, and the uptake for making medicine is in-house."read if there is a line pull Undetermined / FutureHome In addition, IsoDDE's performance claims are based on the company's own technical report, and independent third-party verification and review papers cannot be confirmed in the source of this article.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
No approved pharmaceutical or clinical items FactsHome What we offerJoint Research with Pharmaceutical CompanyThe core is the following two technologies:
| Technology | Primary Information |
|---|---|
| AlphaFold 3 (May 2024) | A new structure using a model fusion model that predicts the structure of complexes including proteins, nucleic acids, low-s, ions, and modification residues. The paper reported that it showed significantly higher accuracy than existing docking methods with protein and low-s interactions. Isomorphic Labs’ article explains: ‘At least 50% improvement from existing methods by interacting with other’s and proteins’ |
| Isomorphic Labs Drug Design Engine | A design system that summarizes the prediction of structure prediction, combined pocket discovery and binding affinity. Technical report claims affinity prediction that exceeds the antibodies and antigen interfaces, CDR-H3 loops, and physical calculations (FEP+, etc.) with more than twice the accuracy of AlphaFold 3 in unknown compounds and pockets. |
| Target modalities | Low-s, antibody, peptides, and curular grooves (J&J partnership release). Technical introduction page explains ‘from low-s to biopharmaceutical’ |
| Role sharing in partnership | In partnership with J&J, Isomorphic Labs takes on prediction and design on the computer, and J&J takes on the evaluation and promotion of experiments. |
AlphaFold 3 and IsoDDE predictWhere and where the drug candidate s bind to the target protein, in what formHome FactsHome This is a problem of the most common flow of drug discovery, if this is fast and accurate, the number of synthesis and measurement is reduced.How to dissolve in water, how to solidify as a crystal, how stable it is as a tablet or injectable solution, where to carry in the bodyremains as another problem. If it is not stated that the other party is responsible for evaluation of experiments in cooperation with J&J, Isomorphic Labs is a pharmaceutical companyIt indicates that the shareholder is now.
In addition, this model was actually determined by X-ray crystal structure analysis and cryo electron microscopeStructure data of protein and complexIsoDDE’s technical report focuses on the panification of compounds and pockets that are not in learning data. It indicates that the bias and amount of structural data obtained in the experiment determines the limits of prediction. Isomorphic Labs does not disclose how much structure data is made in our laboratory. Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| No clinical demonstration | Clinical trials led as of September 2026 have not been published. Not validated for this company | Facts |
| Financial Invisible | Non-listed sales, profit and loss, and R&D expenses are not disclosed. I can not confirm the consumption rate of procurement funds from outside | Undetermined / Future |
| Performance in-house presentation | IsoDDE's performance is a company's technical report, and independent verification is not confirmed by the source of this article. | Facts |
| Experiment and formulation depend on other companies | At least in partnership with J&J, the other party is responsible for experiment evaluation. Many of the processes that finish the prediction into the drug depend on the partner’s ability | |
| Changes in relationship with Alphabet | The ratio of external investors increases, and the conditions of sharing capital and technology with parent companies may change in the future. Current conditions are not disclosed | |
| Manager | CEO Hasabisu leads Google DeepMind. In January 2026, the president established a system to supervise daily operations. | Facts |
12. Glossary
- AlphaFold
- AlphaFold 3 predicts the three-dimensional structure of proteins from amino acid sequences. The third edition also predicts complexes with candidate drugs.
- Google DeepMind
- Alphabet’s AI research organization. Isomorphic Labs developed AlphaFold.
- IsoDDE
- Isomorphic Labs Predicting the strength of structures, binding sites and bonds.
- Connectivity
- The strength of the drug target is difficult to use as a medicine, whether it is too strong or too weak.
- More
- A low-。 that sticks two proteins like “nori”. There are applications that combine the protein that you want to decompose into the decomposition device.
- FEP+
- One of the most common methods based on physical calculation, which estimates the difference in binding strength by dynamic calculation.
- CDR-H3 Loop
- The area where antibodies identify the antigen is most diverse and difficult to predict.
- Other Bets
- Alphabet reports other than Google.
Concept diagram of AI generation13. Source
- Isomorphic Labs In November 1, 2021, Demis Hasabis (Isomorphic Labs) announced that AlphaFold 2 was developed from the AlphaFold. https://www.isomorphiclabs.com/articles/introducing-isomorphic-labs
- Isomorphic Labs Isomorphic Labs Announces Strategic Multi Target Research Collaboration with Lilly $45 million in advance, milestone up to $1.7 billion, royalty, autonomous operation within Alphabet, established from 。Mind, based in Rozanne, London. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_LILLY_07_01_24.pdf
- Isomorphic Labs Isomorphic Labs announced a strategic multi-target research collaboration with Novembers, committing $35 million in advance, a partial burden on research expenses, up to $12 billion in milestones, and three unpublished targets. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_NOVARTIS_07_01_24.pdf
- Isomorphic Labs Isomorphic Labs Announces Nov)s Collaboration Expansion (February 18, 2025) Add up to 3 programs. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC%20LABS_NOVARTIS_18_02_25.pdf
- Isomorphic Labs Isomorphic Labs Announces $600 Million Funding (March 31, 2025) First external procurement, investor, and company program to clinical development, our own program centered on cancer and immune. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_31-03-25.pdf
- Isomorphic Labs Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence History of Chief Medical Officer, Cambridge, USA https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_CMO_US_17-06-25.pdf
- Isomorphic Labs Isomorphic Labs to appoint Max Jaderberg as President (November 26, 2025) More than 300 employees https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_PRESIDENT_APPOINTMENT.pdf
- Isomorphic Labs Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson (January 20, 2026). Joint research, role sharing and target modalities. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/Isomorphic_Labs_Enters_into_a_Research_Collaboration_with_Johnson_Johnson.pdf
- Isomorphic Labs https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/isodde_technical_report.pdf
- Isomorphic Labs Isomorphic Labs secures $2.1 Billion funding Partner with the head office and affiliated company, as the use of investors and funds of Series B. https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_12-05-26.pdf
- Isomorphic Labs "AlphaFold 3 predicts the structure and interactions of all of life's lifes" Co-development with Google DeepMind and release of code for academic purposes. https://www.isomorphiclabs.com/articles/alphafold-3-predicts-the-structure-and-interactions-of-all-of-lifes-molecules
- Isomorphic Labs Isomorphic Labs Announces New Lausanne Location Head office of EPFL Innovation Park and London. Cross, London. https://www.isomorphiclabs.com/articles/isomorphic-labs-has-announced-the-opening-of-its-new-offices-in-lausanne-switzerland
- Isomorphic Labs Our Tech Integrated design engine, proprietary data and large-scale GPUs, low molecular weight to biopharmaceuticals, and their own cancer centered on cancer and immune. https://www.isomorphiclabs.com/our-tech
- Nature "Accurate structure prediction of bio interactions with AlphaFold 3" Nature 630, 493 (May 8, 2024). The structure and performance of AlphaFold 3, the author's affiliation (Google DeepMind・Isomorphic Labs). https://www.nature.com/articles/s41586-024-07487-w
- Alphabet Inc. Form 10K for the) year ended December 31, 2025 Isomorphic Labs https://www.sec.gov/Archives/edgar/data/1652044/000165204426000018/goog-20251231.htm
- Nobel Foundation Press release of the Nobel Prize in 2024. Received a protein structure prediction to Mr. Hasabis and Mr. Jumper (Google DeepMind). https://www.nobelprize.org/prizes/chemistry/2024/press-release/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Established in 2021 as a new company of Alphabet. | Facts | Source 1 https://www.isomorphiclabs.com/articles/introducing-isomorphic-labs |
| Being an autonomous subsidiary of Alphabet, which was launched from DeepMind, CEO has jointly established Google DeepMind | Facts | Source 2 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_LILLY_07_01_24.pdf |
| Partnership with Lilly (prepaid $45 million, milestone up to $17 billion, low)) | Facts | Source 2 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_LILLY_07_01_24.pdf |
| Expansion of partnership with Nov)s (prepaid $37.5 million, milestone up to $12 billion) in 2025 | Facts | Source 3・4 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_NOVARTIS_07_01_24.pdf |
| $6 billion source, investor, policy for clinical practice, cancer and immune center | Facts | Source 5 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_31-03-25.pdf |
| Appointment of Chief Medical Officer and Cambridge, USA | Facts | Source 6 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_CMO_US_17-06-25.pdf |
| More than 300 employees | Facts | Source 7 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_PRESIDENT_APPOINTMENT.pdf |
| Joint research, role sharing with J&J, target modalities | Facts | Source 8 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/Isomorphic_Labs_Enters_into_a_Research_Collaboration_with_Johnson_Johnson.pdf |
| IsoDDE's composition and performance claims (company technical report) | Facts | Source 9 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/isodde_technical_report.pdf |
| $2.1 billion Series B round, investors, use of proceeds, headquarters, and locations | Facts | Source 10 https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_12-05-26.pdf |
| Co-development with Google DeepMind from AlphaFold 3, Publication of Code for Academic Purposes (November 2024) | Facts | Source11 https://www.isomorphiclabs.com/articles/alphafold-3-predicts-the-structure-and-interactions-of-all-of-lifes-molecules |
| The structure and performance of AlphaFold 3 and the affiliation of the author (Google DeepMind・Isomorphic Labs) | Facts | Reference14 https://www.nature.com/articles/s41586-024-07487-w |
| Opened the EPFL Innovation Park and Cross Headquarters in May 2023. | Facts | Source12 https://www.isomorphiclabs.com/articles/isomorphic-labs-has-announced-the-opening-of-its-new-offices-in-lausanne-switzerland |
| Original data and large-scale GPUs, low molecular weight to biopharmaceuticals, and our own cancer centered on cancer and immune | Facts | Reference13 https://www.isomorphiclabs.com/our-tech |
| Non-sure of Alphabet’s other achievements | Facts | Source15 https://www.sec.gov/Archives/edgar/data/1652044/000165204426000018/goog-20251231.htm |
| 2024 Novel Chemical Award (Hassabis, Jumper, Protein Structure Prediction) | Facts | Source16 https://www.nobelprize.org/prizes/chemistry/2024/press-release/ |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Total of public funds: 288,250 million | The calculation of this paper | Total amount of source 2, 3, 5, 10 Includes different personality funds |
| Earnings, Income, and R&D Costs from Alphabet before March 2025 | Undetermined / Future | Unlisted due to unlisted This article does not estimate |
| Target and Prog of Clinical Trials, Target Diseases, Candidates, J&J Affiliates, Lilly and Nov s | Undetermined / Future | Not specified in Source 2-10. The number of reports is not adopted https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC_LABS_FUNDING_12-05-26.pdf |
| What Clinical Trials Cannot See in ClinicalTrials.gov | Undetermined / Future | The result of this article searched the sponsor name in ClinicalTrials.gov (September 26, 2026). Not denying future registration |
| The first clinical product reads the cancer area | Interpre of this paper from the focus area of Source 5 and 6 and the history of Chief Medical Officer | |
| Reading from low-level to biopharmaceuticals | Interpre of this paper from changes in the modalities of the source 2, 3, 8, 9 | |
| Read to maintain competitiveness by separating public technology and internal technology | Interpre of this article from the publication status of Source 9/11 | |
| Read that the source of competitiveness is used for resources and data | Interpre of this paper from the description of source 8 and 13 | |
| Risks of Change in Relation to Alphabet | Interpre of this paper from the composition of the source 8 and 10 roles |
Last Updated:September 26, 2026/Troy Technical
All figures in this article are based on Isomorphic Labs official announcements, legal disclosure documents, review papers (Nature), and Nobel Foundation announcements submitted by the parent company Alphabet to the US Securities and Exchange Commission (SEC). We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.